Private Equity Fund Acquires Protein Technologies

/by

Protein Technologies has fewer than 100 employees, according to a company spokesperson. She told IBO that the investment will be used to increase R&D, and service and field-based technical resources, especially in Europe and Asia.

Wellesley, MA and Tucson, AZ 6/18/15—Ampersand Capital Partners has acquired Protein Technologies, a provider of peptide synthesis instrumentation, for an undisclosed amount. “Protein Technologies is the recognized leader in a segment of the life sciences instrument market that is experiencing strong demand based on worldwide research interest in novel, peptide-based therapies,” said David Parker, general partner at Ampersand. Nate Cosper, PhD, will remain president and CEO.

< | >